Literature DB >> 20570174

Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA).

Harvinder S Chahal1, J Paul Chapple, Lawrence A Frohman, Ashley B Grossman, Márta Korbonits.   

Abstract

Familial pituitary adenomas can occur in MEN1 and Carney complex, as well as in the recently characterized familial isolated pituitary adenoma (FIPA) syndrome. FIPA is an autosomal dominant disease with incomplete penetrance, characterized by early-onset disease, often aggressive tumor growth and a predominance of somatotroph and lactotroph adenomas. In 20% of FIPA families, heterozygous mutations have been described in the aryl hydrocarbon receptor interacting (AIP) gene, whereas in other families the causative gene(s) are unknown. It has been suggested that AIP is a tumor suppressor gene and although experimental data support this hypothesis, the exact molecular mechanism by which its disruption leads to tumorigenesis is unclear. Here we discuss the clinical, genetic and molecular features of patients with FIPA. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570174     DOI: 10.1016/j.tem.2010.02.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  31 in total

Review 1.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

2.  Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas?

Authors:  Sema Yarman; Yeliz Duvarci Ogret; Fatma Savran Oguz
Journal:  Genet Test Mol Biomarkers       Date:  2015-05-04

Review 3.  The glucocorticoid receptor and its expression in the anterior pituitary and the adrenal cortex: a source of variation in hypothalamic-pituitary-adrenal axis function; implications for pituitary and adrenal tumors.

Authors:  George Briassoulis; Svetozar Damjanovic; Paraskevi Xekouki; Hervé Lefebvre; Constantine A Stratakis
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

4.  Aryl Hydrocarbon Receptor Interacting Protein Targets IRF7 to Suppress Antiviral Signaling and the Induction of Type I Interferon.

Authors:  Qinjie Zhou; Alfonso Lavorgna; Melissa Bowman; John Hiscott; Edward W Harhaj
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

5.  A novel germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene in an Italian family with gigantism.

Authors:  C Urbani; D Russo; F Raggi; M Lombardi; C Sardella; I Scattina; I Lupi; L Manetti; L Tomisti; C Marcocci; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2014-07-05       Impact factor: 4.256

Review 6.  Familial isolated pituitary adenomas: an emerging clinical entity.

Authors:  F Martucci; G Trivellin; M Korbonits
Journal:  J Endocrinol Invest       Date:  2012-12       Impact factor: 4.256

Review 7.  The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas.

Authors:  Catrin Lloyd; Ashley Grossman
Journal:  Endocrine       Date:  2013-12-24       Impact factor: 3.633

Review 8.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

9.  Should aip gene screening be recommended in family members of FIPA patients with R16H variant?

Authors:  Maria Chiara Zatelli; Maria Luisa Torre; Rachele Rossi; Marta Ragonese; Francesco Trimarchi; Ettore degli Uberti; Salvatore Cannavò
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

Review 10.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.